Digoxin and propranolol in the prophylaxis of dysrhythmias after coronary artery bypass grafting

Circulation
|September 1, 1983
PubMed

Insights

Post-coronary artery bypass grafting (CABG) digoxin and propranolol significantly reduced serious dysrhythmias. This drug regimen prevented supraventricular and ventricular arrhythmias in patients within the first week after CABG.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Pharmacology

Background:

  • Serious tachydysrhythmias affect 10-30% of patients post-coronary artery bypass grafting (CABG).
  • Preventing these early post-CABG dysrhythmias is crucial for patient outcomes.

Purpose of the Study:

  • To investigate the efficacy of digoxin and propranolol in preventing serious dysrhythmias after CABG.
  • To assess the safety and incidence of dysrhythmias in patients receiving post-operative cardiac medications.

Main Methods:

  • A randomized controlled trial involving 179 patients undergoing CABG.
  • Patients were assigned to either a drug group (digoxin and propranolol) or a control group.
  • Exclusion criteria included pre-CABG digoxin use, low ejection fraction, pre-existing dysrhythmias, and pacer dependency.

Main Results:

  • The drug group showed significantly lower rates of supraventricular dysrhythmias (3.4% vs. 30%, p < .001).
  • Ventricular dysrhythmias were also significantly reduced in the drug group (1.1% vs. 8.9%, p < .01).
  • No adverse reactions were reported with the digoxin and propranolol regimen.

Conclusions:

  • A post-CABG regimen of digoxin and propranolol effectively reduces the incidence of supraventricular and ventricular dysrhythmias.
  • This combination therapy is safe and well-tolerated in the early post-operative period after CABG.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...